NCT05368051Unknown不适用
Multi-omics Model Predicts Efficacy of Preoperative Neoadjuvant Chemoradiotherapy Combined PD-1 Antibody Therapy for Locally Advanced Rectal Cancer
适应症
试验速览
- 阶段
- 不适用
- 入组人数
- 30
- 试验地点
- 1
- 主要终点
- pathologic complete response（pCR）
研究概览
简要总结
The purpose of this clinical research is to establish a multi-omics model based on genomics，transcriptomics，gut microbiota in predicting pathologic response after neoadjuvant chemoradiotherapy combined PD-1 antibody given to patients with locally advanced rectal cancer.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients have been fully aware of the content of this study and signed the informed consent voluntarily;
- •Patients with rectal cancers must satisfied all the following conditions: Stage II/III LARC (cT1-3N1-2M0)；Tumor distal location ≤ 7 cm from anal verge (MRI diagnosed);
- •Patients regardless of gender with aged ≥18 years and ECOG score of 0 or 1;
- •Physical and viscera function of patients can withstand major abdominal surgery;
- •Patients are willing and able to follow the study protocol during the study;
- •Patients give consent to the use of blood and pathological specimens for study;
- •Within 28 days prior to enrolment, we must confirm a negative serological pregnancy test for child-bearing age women and they agree to use effective contraception for the duration of drug use and for 60 days after the last dose.
排除标准
- •Patients have a present or previous active malignancy except the diagnosis of rectal cancer this time;
- •Patients underwent major surgery within 4 weeks prior to study treatment;
- •Patients have any condition affects the absorption of capecitabine through gastrointestinal tract;
- •Patients have severe uncontrolled recurrent infections, or other severe uncontrolled concomitant diseases;
- •Patients who are allergic to any of the ingredients under study;
- •Patients with severe concomitant diseases with estimated survival ≤ 5 years;
- •Patients with present or previous moderate or severe liver and kidney damage presently or previously;
- •Patients have received other study medications or any immunotherapy currently or in the past;
- •Patients preparing for or previously received organ or bone marrow transplant;
- •Patients who received immunosuppressive or systemic hormone therapy for immunosuppressive purposes within 1 month prior to the initiation of study therapy;
- •Patients with congenital or acquired immune deficiency (such as HIV infection);
- •If patients with a history of uncontrolled epilepsy, central nervous system disease or mental disorder, the investigator will determine whether the clinical severity prevents the signing of informed consent or affects the patient's oral medication compliance;
- •Patients with other factors that may affect the study results or cause the study to be terminated midway, such as alcoholism, drug abuse, other serious diseases (including mental illness) requiring combined treatment and severe laboratory examination abnormalities.
- •Pregnant or lactating women
结局指标
主要结局
pathologic complete response（pCR）
时间窗: 1 year
All the enrolled patients will receive total mesorectal excision (TME) 7-9 weeks after the end of long course radiotherapy. The rectal specimens will be evaluated by the pathologists who are experienced on the rectal cancer diagnosis according to the 1997 Dworak grading system. The rectal cancer will be classified into 5 grades. Grade 0-3 will be considered as non-pCR while grade 4 represent pCR.
次要结局
未报告次要终点
研究者
Zhongtao Zhang
professor
Beijing Friendship Hospital
研究点 (1)
Loading locations...
相似试验
尚未招募
不适用
Clinical Study on the Evaluation of the Efficacy of Cervical CancerUterine Cervical NeoplasmsNCT06254729First Affiliated Hospital Xi'an Jiaotong University4,000
招募中
2 期
Immune Treatment of Brain Metastasis of Lung Cancer Combined With Large-segmentation Precision RadiotherapyNon Small Cell Lung CancerNCT05584267Hunan Province Tumor Hospital140
尚未招募
不适用
The Predictive Value of MRI for Adult-type Diffuse GliomasGliomaNCT06572592First Affiliated Hospital, Sun Yat-Sen University200
招募中
不适用
Dynamic Multi-omics Integration Model to Predict Neoadjuvant Therapy Response in Locally Advanced Rectal CancerPredictive Cancer ModelPathologic Complete ResponseNCT06364371Sixth Affiliated Hospital, Sun Yat-sen University106
已完成
不适用
Predictive Factors of Short/Long-term Outcome and Complications of Bilateral DBS in PDParkinson DiseaseNCT03528460University Hospital, Grenoble420